Wilhelmsfeld, Germany

Achim Feurer

This inventor holds 33 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 8 EPO patents. Top assignees: Bayer Aktiengesellschaft, Bayer Healthcare Aktiengesellschaft, Merck Serono S. a.. Active years: 1998-2014.

USPTO Granted Patents = 33 

% Patents Active = 54.5

 

 

Average Co-Inventor Count = 10.3

ph-index = 16

Forward Citations = 1,018(Granted Patents)


Location History:

  • Odenthal, DE (1998 - 2004)
  • Wilhelmsfeld, DE (2005 - 2010)
  • Auggen, DE (2011 - 2014)

Company Filing History:


Years Active: 1998-2014

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Aryl Amino Pyridine Derivatives
Imidazopyridine Derivatives
Melanocortin-4 Receptor Antagonists
Rho-Kinase Inhibitors
Pyrazolopyridine Derivatives
Pyrimidine Derivatives
Cardiocirculatory Diseases
Heterocyclic Compounds
Bis-Quinoline Compounds
Cerebral Disorders
Sulfonamide Compounds
Condensed Pyrazole Derivatives
33 patents (USPTO):Explore Patents

Title: The Innovative Journey of Achim Feurer

Introduction: Achim Feurer, a talented inventor hailing from Wilhelmsfeld, Germany, has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents: Achim Feurer's latest patents showcase his commitment to pushing the boundaries of technology, with a focus on sustainability and efficiency in various industries.

Career Highlights: Throughout his illustrious career, Achim Feurer has been recognized for his pioneering work in developing cutting-edge solutions that have revolutionized the way we approach challenges in the modern world.

Collaborations: Achim Feurer has collaborated with leading experts in the industry, fostering a culture of innovation and knowledge-sharing that has led to remarkable advancements in technology.

Conclusion: Achim Feurer's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…